Patent 9271978 was granted and assigned to Zenith Epigenetics Corp. on March, 2016 by the United States Patent and Trademark Office.
The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.